Low levels of ATM in breast cancer patients with clinical radiosensitivity

Fang, Zhiming, Kozlov, Sergei, McKay, Michael J., Woods, Rick, Birrell, Geoff, Sprung, Carl N., Murrell, Dédée F., Wangoo, Kiran, Teng, Linda, Lavin, Martin F., Kearsley, John H., Graham, Peter H. and Clarke, Raymond A. (2010) Low levels of ATM in breast cancer patients with clinical radiosensitivity. Genome Integrity, 1 9-1-9-9. doi:10.1186/2041-9414-1-9

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Kozlov_authaffil_staffdata.pdf HERDC evidence – not publicly available application/pdf 374.58KB 3

Author Fang, Zhiming
Kozlov, Sergei
McKay, Michael J.
Woods, Rick
Birrell, Geoff
Sprung, Carl N.
Murrell, Dédée F.
Wangoo, Kiran
Teng, Linda
Lavin, Martin F.
Kearsley, John H.
Graham, Peter H.
Clarke, Raymond A.
Title Low levels of ATM in breast cancer patients with clinical radiosensitivity
Journal name Genome Integrity   Check publisher's open access policy
ISSN 2041-9414
Publication date 2010-06-24
Sub-type Article (original research)
DOI 10.1186/2041-9414-1-9
Open Access Status DOI
Volume 1
Start page 9-1
End page 9-9
Total pages 9
Place of publication London, United Kingdom
Publisher BioMed Central
Collection year 2011
Language eng
Formatted abstract
Background and Purpose: Adjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular interest as they may be at risk of both breast cancer and clinical radiosensitivity. The association of specific ATM gene mutations with these pathologies has been well documented, however, there is uncertainty regarding pathological thresholds for the ATM protein.

Results: Semi-quantitative immuno-blotting provided a reliable and reproducible method to compare levels of the ATM protein for a rare cohort of 20 cancer patients selected on the basis of their severe adverse normal tissue reactions to radiotherapy. We found that 4/12 (33%) of the breast cancer patients with severe adverse normal tissue reactions following radiotherapy had ATM protein levels < 55% compared to the mean for non-reactor controls.

Conclusions
: ATM mutations are generally considered low risk alleles for breast cancer and clinical radiosensitivity. From results reported here we propose a tentative ATM protein threshold of ~55% for high-risk of clinical radiosensitivity for breast cancer
Keyword Breast cancer
Adjuvant radiotherapy
Semi-quantitative immuno-blotting
ATM mutations
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article number 9

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2011 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 18 Feb 2011, 11:33:41 EST by Caroline Irle on behalf of UQ Centre for Clinical Research